On January 22, 2026, Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, announced the closing of a $287 million Series D financing. Wilson Sonsini Goodrich & Rosati advised investor SR One on the transaction.

The financing included participation from new investors, including SR One, TCGX, RA Capital Management, HBM Healthcare Investments, SymBiosis, Adage Capital Management, Invus, SilverArc Capital, and certain other investors. Existing investors RTW Investments and Hengdian Group Capital also participated in this financing.

The proceeds from the fundraise will support the advancement of CX11, a differentiated oral small molecule GLP-1 RA for obese and overweight patients currently being evaluated in a Phase 2 trial conducted by CORXEL in the United States and a Phase 3 trial conducted by Vincentage in China, and other cardiometabolic programs, including for acute ischemic stroke and hypertension.

The Wilson Sonsini team that advised SR One on the transaction included Dan Koeppen, Kassandra Castillo, James Keegan, and Derek Wallace.

For more information, please see CORXEL’s news release. Additional coverage can be found on Fierce Biotech, BioSpace, Longevity.Technology, Axios (subscription required), and The Pharma Letter (subscription required).